BALPHARMA Stock Overview
Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India, Uzbekistan, Guatemala, and Malta.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 3/6 |
Bal Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹100.60 |
| 52 Week High | ₹132.45 |
| 52 Week Low | ₹77.50 |
| Beta | 0.52 |
| 1 Month Change | 1.72% |
| 3 Month Change | -11.17% |
| 1 Year Change | 27.91% |
| 3 Year Change | -14.67% |
| 5 Year Change | 43.41% |
| Change since IPO | 66.69% |
Recent News & Updates
Does Bal Pharma (NSE:BALPHARMA) Have A Healthy Balance Sheet?
Mar 14
Bal Pharma Limited's (NSE:BALPHARMA) 26% Share Price Surge Not Quite Adding Up
Feb 01Recent updates
Does Bal Pharma (NSE:BALPHARMA) Have A Healthy Balance Sheet?
Mar 14Bal Pharma Limited's (NSE:BALPHARMA) 26% Share Price Surge Not Quite Adding Up
Feb 01Bal Pharma Limited's (NSE:BALPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 18Bal Pharma (NSE:BALPHARMA) Is Due To Pay A Dividend Of ₹1.00
Aug 28Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00
Aug 14Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00
Aug 17Bal Pharma (NSE:BALPHARMA) Has Announced A Dividend Of ₹1.00
Jul 31Is Bal Pharma (NSE:BALPHARMA) Using Too Much Debt?
Mar 08Bal Pharma (NSE:BALPHARMA) Use Of Debt Could Be Considered Risky
Nov 23Does Bal Pharma Limited (NSE:BALPHARMA) Have A Place In Your Dividend Stock Portfolio?
Aug 10
Should You Buy Bal Pharma Limited (NSE:BALPHARMA) For Its 2.3% Dividend?
Aug 10Shareholder Returns
| BALPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.3% | -0.5% | 1.4% |
| 1Y | 27.9% | 55.3% | 46.1% |
Return vs Industry: BALPHARMA underperformed the Indian Pharmaceuticals industry which returned 55.3% over the past year.
Return vs Market: BALPHARMA underperformed the Indian Market which returned 46.1% over the past year.
Price Volatility
| BALPHARMA volatility | |
|---|---|
| BALPHARMA Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: BALPHARMA's share price has been volatile over the past 3 months.
Volatility Over Time: BALPHARMA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 869 | Shailesh Siroya | www.balpharma.com |
Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India, Uzbekistan, Guatemala, and Malta. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives. It provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands.
Bal Pharma Limited Fundamentals Summary
| BALPHARMA fundamental statistics | |
|---|---|
| Market cap | ₹1.58b |
| Earnings (TTM) | ₹35.19m |
| Revenue (TTM) | ₹3.27b |
45.0x
P/E Ratio0.5x
P/S RatioIs BALPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BALPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹3.27b |
| Cost of Revenue | ₹1.88b |
| Gross Profit | ₹1.39b |
| Other Expenses | ₹1.35b |
| Earnings | ₹35.19m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.24 |
| Gross Margin | 42.36% |
| Net Profit Margin | 1.08% |
| Debt/Equity Ratio | 223.2% |
How did BALPHARMA perform over the long term?
See historical performance and comparison